At a glance
- Originator Kyowa Hakko
- Class Antiallergics; Antiplatelets; Benzazepines; Small molecules
- Mechanism of Action Thromboxane synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 28 May 2001 Discontinued-Preclinical for Thrombosis in Japan (Unknown route)
- 22 Sep 1998 No-Development-Reported for Thrombosis in Japan (Unknown route)
- 13 Nov 1995 New profile